1 Outlook 2018: excluding the effects from the acquisition of NxStage Medical, Inc. and Sound Physicians divestment.
2 Results 2017: adjusted for impacts from IFRS 15 implementation of €486 M.
3 Key performance indicator used for internal management.
4 Excluding the 2018 Sound Valuation Impact.
5 Net income attributable to shareholders of FMC AG & Co. KGaA.
6 Excluding the 2017 impacts from the VA Agreement, Natural Disaster Costs, FCPA related charge, as well as the impacts from the U.S. Tax Reform.
7 Full-time equivalents.
At the end of 2017, around 3.2 million patients received dialysis. According to estimates, the number of people worldwide suffering from chronic kidney failure and requiring dialysis treatment is rising at a relatively constant rate of around 6 % annually. It is expected to reach more than 3.4 million patients in 2018 and approximately 4.9 million by 2025. Social trends contribute to this rise in patient numbers. In Europe and the U.S. in particular, they include the aging population and the increasing incidence of diabetes and hypertension, two illnesses that frequently precede the onset of end-stage renal disease. In developing and emerging countries, the growing population and gradually improved access to dialysis as a result fo increasing wealth are key factors that further boost demand for dialysis products and services. We want to continue to make a significant contribution to meeting this demand in the future.
Based on our strategic core competencies, we set ourselves long-term targets in 2014 with our growth
strategy 2020 ( Vision 2020 ):